Click on image to open expanded view
Item No.
49897
You may also like
Product Description
If your horse is having problems associated with navicular syndrome Osphos Inj 60 can help alleviate their symptoms and slow down the progression of the disease. Easy to use vials are ready to use and don't require any dilution.
What is Osphos Inj 60mg/mL, 15 ml?
OSPHOS is an injectable bisphosphonate solution for the control of clinical signs associated with navicular syndrome in horses four years and older. OSPHOS inhibits bone resorption by binding to calcium phosphate crystals (inhibiting their formation and dissolution), and by exerting direct cellular effects on osteoclasts. OSPHOS is supplied as 15 mL (900 mg) of clodronate disodium (60 mg/mL) per vial and is ready-to-use (no reconstitution or dilution required).
Who is Osphos Inj 60mg/mL, 15 ml for?
Horses
Why use Osphos Inj 60mg/mL, 15 ml?
-For Horses (Equine) four years and older
-Clodronate injection (60mg per mL)
-The Only Intramuscular Option -- Injectable bisphosphonate solution for the control of clinical signs associated with navicular syndrome
-When radiographic signs indicative of bony changes associated with navicular syndrome are present, OSPHOS is a clear choice.
-OSPHOS inhibits bone resorption by binding to calcium phosphate crystals (inhibiting their formation and dissolution), and by exerting direct cellular effects on osteoclasts.
How does Osphos Inj 60mg/mL, 15 ml work?
OSPHOS inhibits bone resorption by binding to calcium phosphate crystals (inhibiting their formation and dissolution), and by exerting direct cellular effects on osteoclasts.
Manufacturer:
Dechra Pharmaceuticals
Active Ingredients(s):
Osphos intramuscular injection contains the bisphosphonate Clodronic acid
How is Osphos Inj 60mg/mL, 15 ml sold?
Osphos Inj 60mg/mL is sold in 15ml - single use vial
What are the side effects of Osphos Inj 60mg/mL, 15 ml?
In field studies, the most common side effects reported were signs of discomfort or nervousness, cramping, pawing and/or colic within 2 hours post-treatment (9% of horses treated: n=10). Eight out of ten of these horses had resolution of their clinical signs with 10 to 15 minutes of hand walking. In one horse, clinical signs resolved without hand walking. Only one experienced colic requiring treatment. That horse also developed hives and recovered after treatment with flunixin and dexamethasone.
What special precautions are there?
Keep out of reach of children
What to do if overdose?
Contact your nearest emergency animal hospital
How can I store Osphos Inj 60mg/mL, 15 ml?
Store in a cool and dry place
Helpful Tips:
OSPHOS is administered at 1.8 mg/kg by intramuscular injection up to a maximum dose of 900 mg per horse (one vial). Divide the total volume evenly into three separate injection sites. Discard unused vial contents. OSPHOS is provided in a single use vial and does not contain a preservative. If there is no response to initial therapy, the horse should be re-evaluated. For horses that initially respond to OSPHOS but do not maintain their clinical improvement for 6 months, OSPHOS may be re-administered at 3 to 6 month intervals based on recurrence of clinical signs. For horses that respond to OSPHOS and maintain clinical improvement for 6 months, OSPHOS should be re-administered after clinical signs recur.
Overview
OSPHOS is administered at 1.8 mg/kg by intramuscular injection up to a maximum dose of 900 mg per horse (one vial). Divide the total volume evenly into three separate injection sites. Discard unused vial contents. OSPHOS is provided in a single use vial and does not contain a preservative.
If there is no response to initial therapy, the horse should be re-evaluated. For horses that initially respond to OSPHOS but do not maintain their clinical improvement for 6 months, OSPHOS may be re-administered at 3 to 6 month intervals based on recurrence of clinical signs. For horses that respond to OSPHOS and maintain clinical improvement for 6 months, OSPHOS should be re-administered after clinical signs recur
Main Ingredients
Osphos intramuscular injection contains the bisphosphonate Clodronic acid